<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="8314">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02011204</url>
  </required_header>
  <id_info>
    <org_study_id>2013P001505</org_study_id>
    <nct_id>NCT02011204</nct_id>
  </id_info>
  <brief_title>Study of Electrical Impedance Myography (EIM) in ALS</brief_title>
  <official_title>Noninvasive Assessment of Neuromuscular Disease Using Electrical Impedance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>State University of New York - Upstate Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Skulpt, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>State University of New York - Upstate Medical University</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is studying Electrical Impedance Myography (EIM) for measuring muscle health.
      The trial is studying people with Amyotrophic Lateral Sclerosis (ALS),  other neuromuscular
      diseases, and healthy volunteers to see if the EIM device can measure disease in muscle
      tissue.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, 9-month study evaluating the effectiveness of electrical impedance
      myography (EIM) as a diagnostic and disease-tracking tool.  In addition, the following will
      be studied:

        1. Determine EIM device's ability to discriminate between ALS and &quot;look-alike&quot; non-fatal,
           motor-predominant syndromes;

        2. Track EIM progression over time and determine the best summary EIM measure that could
           serve as an endpoint in future clinical trials and individual patient care; and,

        3. Determine whether EIM progression is predictive of a combined outcome of survival and
           progression as measured by ALS Functional Rating Scale, Revised (ALSFRS-R), Hand-held
           Dynamometry (HHD) and Vital Capacity (VC) measures.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">April 2015</completion_date>
  <primary_completion_date type="Anticipated">April 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Discrimination between Groups</measure>
    <time_frame>Duration of the Study (9 months for Group A, one visit for Groups B and C)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Determine EIM device's ability to discriminate between ALS and &quot;look-alike&quot; non-fatal, motor-predominant syndromes</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tracking Progression</measure>
    <time_frame>Duration of Study, (9 months for Group A, one visit for Groups B and C)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Track EIM progression over time and determine the best summary EIM measure that could serve as an endpoint in future clinical trials and individual patient care</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation with Outcome Measures</measure>
    <time_frame>Duration of Study (9 months for Group A, one visit for Groups B and C)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Determine whether EIM progression is predictive of a combined outcome of survival and progression as measured by ALSFRS-R, HHD and VC.</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <condition>Motor Neuron Disease</condition>
  <condition>Charcot-Marie-Tooth Disease</condition>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>People with ALS</arm_group_label>
    <description>People diagnosed with early ALS (possible, probable, or probable-laboratory supported ALS according to El Escorial criteria)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Other Neurological Diseases</arm_group_label>
    <description>People with a diagnosis of a disease that mimics ALS</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Controls</arm_group_label>
    <description>Healthy Volunteers that do not have ALS or another neurological disease that mimics ALS.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Electrical impedance myography (EIM)</intervention_name>
    <description>In EIM, high-frequency alternating electrical current is applied to localized areas of muscle via surface electrodes and the consequent surface voltage patterns analyzed.
EIM is very sensitive to the compositional and structural elements of muscle. Data from both human subjects and animal disease models, including ALS, spinal muscular atrophy (SMA), and Duchenne muscular dystrophy (DMD), show that EIM may be sensitive to a variety of pathological states. It is anticipated that EIM will thus likely be able to assist in quantifying the severity of the disease affecting various muscle groups as well as in measuring changes in the disease over time.</description>
    <arm_group_label>People with ALS</arm_group_label>
    <arm_group_label>Other Neurological Diseases</arm_group_label>
    <arm_group_label>Healthy Controls</arm_group_label>
    <other_name>EIM1102 device</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        People with ALS People diagnosed with early ALS (possible, probable, or probable-
        laboratory supported ALS according to El Escorial criteria)

        Other Neurological Diseases People with a diagnosis of a disease that mimics ALS

        Healthy Controls Healthy Volunteers that do not have ALS or another neurological disease
        that mimics ALS.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Early ALS Inclusion Criteria:

          -  Sporadic or familial ALS (as defined by revised El Escorial criteria)

          -  Onset of weakness or spasticity due to ALS ≤ 24 months prior to the
             Screening/Baseline Visit.

          -  Slow vital capacity (SVC) ≥60% of predicted for gender, height, and age

        Early ALS Exclusion Criteria:

          -  Diagnosis of definite ALS

          -  The presence of unstable psychiatric disease, cognitive impairment, or dementia that
             would impair ability of the subject to provide informed consent, or a history of
             active substance abuse within the prior year.

        ALS Disease Mimics Inclusion Criteria:

        - Diagnosis of one of the following:

        a. Pure Lower Motor Neuron Disease (LMND) mimics: i. Multi-focal motor neuropathy ii.
        Autoimmune motor neuropathy iii. Cervical or lumbosacral radiculopathies with weakness
        involving more than one extremity or more than a single myotome if restricted to one
        extremity.

        iv. Multiple peripheral mononeuropathies with clinical weakness v. Charcot-Marie-Tooth
        Disease b. Pure Upper Motor Neuron Disease (UMND) mimics: i. Cervical myelopathy ii.
        Multiple sclerosis iii. Hereditary spastic paraparesis

        ALS Disease Mimics Exclusion Criteria:

          -  Diagnosis of possible, probable, probable-laboratory supported, or definite ALS

          -  Presence of positive family history of ALS.

          -  The presence of unstable psychiatric disease, cognitive impairment, or dementia that
             would impair ability of the subject to provide informed consent, or a history of
             active substance abuse within the prior year.

        Healthy Volunteer Inclusion Criteria:

        - Absence of a known neurological disorder.

        Healthy Volunteer Exclusion Criteria:

          -  History of ALS, myopathy, neuropathy, ALS mimic disorder or other neurodegenerative
             disease.

          -  Presence of positive family history of ALS.

          -  The presence of unstable psychiatric disease, cognitive impairment, or dementia that
             would impair ability of the subject to provide informed consent,  or a history of
             active substance abuse within the prior year.

        *Please note that this is not a complete listing on all eligibility criteria.*
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeremy Shefner, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>State University of New York - Upstate Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Casey Brescia</last_name>
    <phone>617-643-7434</phone>
    <email>cbrescia@partners.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Miami Miller School of Medicine</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sumaira Hussain</last_name>
      <phone>305-243-8487</phone>
      <email>sumaira.hussain@med.miami.edu</email>
    </contact>
    <investigator>
      <last_name>Michael Benatar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Theodore Peng</last_name>
      <phone>617-643-2522</phone>
      <email>tpeng1@partners.org</email>
    </contact>
    <investigator>
      <last_name>William David, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Skulpt, Inc</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Martino</last_name>
      <phone>888-382-8824</phone>
      <email>jennifer@skulpt.me</email>
    </contact>
    <investigator>
      <last_name>Erik Ensrud, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SUNY Upstate Medical University</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tanya Perry</last_name>
      <phone>315-464-4998</phone>
      <email>perryt@upstate.edu</email>
    </contact>
    <investigator>
      <last_name>Jeremy Shefner, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Health Sciences</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mozhdeh Marandi</last_name>
      <phone>336-713-8577</phone>
      <email>mmarandi@wakehealth.edu</email>
    </contact>
    <investigator>
      <last_name>James Carress, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 10, 2014</lastchanged_date>
  <firstreceived_date>December 3, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>State University of New York - Upstate Medical University</investigator_affiliation>
    <investigator_full_name>Jeremy Shefner</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Charcot-Marie-Tooth Disease</mesh_term>
    <mesh_term>Nerve Compression Syndromes</mesh_term>
    <mesh_term>Hereditary Sensory and Motor Neuropathy</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Neuromuscular Diseases</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Tooth Diseases</mesh_term>
    <mesh_term>Motor Neuron Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
